Stress and coping: The psychoneuroimmunology of HIV/AIDS

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 4, 1999, Pages 615-633

  Balbin, Elizabeth G ^b   Ironson, Gail H ^a   Solomon, George F ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE

Author keywords

AIDS; Disease progression; HIV; HIV long term survivors; Immunity; Life change events; PNI; Psychology and HIV; Psychoneuroimmunology; Stress

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL FACTOR; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AVOIDANCE BEHAVIOR; COPING BEHAVIOR; DEMENTIA; DEPRESSION; DISEASE COURSE; DOCTOR PATIENT RELATION; EMOTIONALITY; HEREDITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIFE EVENT; LYMPHOCYTE COUNT; MORBIDITY; MORTALITY; NEGATIVE SYNDROME; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; PATHOPHYSIOLOGY; PREDICTION; REVIEW; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; STRESS; SURVIVAL; T LYMPHOCYTE; VIRULENCE; VIRUS STRAIN;

EID: 0033508772     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0047     Document Type: Article

References (133)

1. Lockard V G, Grogan J B, Brunson J G. Alterations in the bactericidal ability of rabbit alveolar macrophages as a result of tumbling stress. American Journal of Pathology. 70:1970;57-59.
2. Ishigami T. The influence of psychic acts on the progress of pulmonary tuberculosis. American Review of Tuberculosis. 2:1919;470-484.
3. Kasl S V, Evans A S, Niederman J C. Psychosocial risk factors in the development of infectious mononucleosis. Psychosomatic Medicine. 41:1979;445-466.
4. Cohen S, Tyrell D AJ, Smith A P. Psychosocial stress and susceptibility to the common cold. New England Journal of Medicine. 123:1991;329-331.
5. Merson M H. Slowing the spread of HIV: agenda for the 1990s. Science. 260:1993;1266.
6. Weekly Epidemiological Record. 48:1996;361.
7. Oliva D, Glatt A E. HIV Infection: Epidemiology, Transmission, and Screening. Hospital Medicine. 35:1991;31-37.
8. Fauci A S. The scientific agenda for AIDS. Issues in Science and Technology. 4:1988;33-42.
9. Stine G J. AIDS Update. 1996;Prentice-Hall, Upper Saddle River. p. 112-114.
10. Blaxhult A, Lidman K. Current treatment of HIV infection. Nordic Medicine. 113:1998;290-292.
11. Sendi P P, Bucher H C, Craig B A. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-Infected population in the era of antiretroviral triple combination therapy. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 20:1999;376-381.
12. Chaisson R E. The changing natural history of HIV/AIDS in the 'HAART' era: clinical implications. Medscape HIV/AIDS. 4:1998;2.
13. Durant J, Clevenbergh P, Halfon P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 353:1999;2195-2199.
14. Horuk R. Chemokine receptors and HIV-1 the fusion of two major research fields. Immunology Today. 20:1999;89-94.
15. Hendel H, Henon N, Lebuanec H. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 19:1998;381-386.
16. McNicholl J M, Smith D K, Qari S H, Hodge T. Host genes and HIV: the role of the chemokine receptor gene CCR% and its allele (Δ 32 CCR5). Emerging Infectious Diseases. 3:1997;261-271.
17. Mann D L, Garner R P, Dayhoff D E. Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans. Journal of Infectious Diseases. 178:1998;1799-1802.
18. Carrington M, Nelson G W, Martin M P. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 283:1999;1748-1752.
19. Alioum A, Leroy V, Commenges D. Effects of gender, age transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov modes. Epidemiology. 9:1998;605-612.
20. Rezza G. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 17:1998;S13-S16.
21. von Overbeck J, Egger M, Smith G D. Survival in HIV infection: do sex and category of transmission matter? AIDS. 8:1994;1307-1313.
22. Webber M P, Schoenbaum E E, Gourevitch M N. A prospective study of HIV disease progression in female and male drug users. AIDS. 13:1999;257-262.
23. Farzadegan H, Hoover D R, Astemborski J. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 352:1998;1510-1514.
24. Kanki P J, Hamel D J, Sankale J L. Human immunodeficiency virus type 1 subtypes differ in disease progression. Journal of Infectious Diseases. 179:1999;68-73.
25. +T-cell count. Journal of Medical Virology. 56:1998;259-263.
26. Roos M T, Prins M, Koot M. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS. 12:1998;1745-1751.
27. Fahey J L, Taylor J M, Manna B. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 12:1998;1581-1590.
28. Staszewski S, DeMasi R, Hill A M, Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS. 12:1998;1991-1997.
29. +cell count falls below 200/microL. International Journal of Epidemiology. 27:1998;897-903.
30. Cozzi-Lepri A, Sabin C A, Phillips A N. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. Epidemiology and Infection. 121:1998;369-376.
31. Perneger T V, Yerly S, Perril L. Transforming laboratory test results to improve clinical outcome predictions in HIV patients. Swiss Cohort Study. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology. 17:1998;442-449.
32. +T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
33. Yang O O. CD8 T cells in HIV infection: mechanisms of immunity. Hospital Practice. 33:1998;105-108.
34. Barker E, Mackewicz C E, Reyes-Teran G. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquire immunodeficiency syndrome. Blood. 92:1998;3105-3114.
35. +T cells predicts HIV disease progression. Cytometry. 33:1998;133-137.
36. Safrit J T, Koup R A. The immunology of primary HIV infection: which immune responses control HIV replication? Current Opinion in Immunology. 7:1995;456-461.
37. Bernard N F, Yannakis C M, Lee J S, Tsoukas C M. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. Journal of Infectious Diseases. 179:1999;538-547.
38. Klein M R, van der Burg S H, Pontesilli O, Miedema F. Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? Immunology Today. 19:1998;317-324.
39. Stranford S A, Skurnick J, Louria D. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proceedings of the National Academy of Sciences of the USA. 96:1999;1030-1035.
40. +T cells. Immunology Today. 17:1996;217-224.
41. Cao Y, Qun L, Zhang L. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New England Journal of Medicine. 332:1995;201-208.
42. Loomis-Price L D, Cox J H, Mascola J R. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. Journal of Infectious Diseases. 178:1998;1306-1316.
43. Popper S J, Sankale J L, Thior I. Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. AIDS Research and Human Retroviruses. 14:1998;1157-1162.
44. +T-cell counts and T-cell function in long-term AIDS-free infection. AIDS. 12:1998;1591-1600.
45. +T cell depletion in HIV-1 infected individuals. Microbial Pathogenesis. 25:1998;253-266.
46. Oliva A, Kinter A L, Vaccarezza. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. Journal of Clinical Investigation. 102:1998;223-231.
47. Brunsgaard H, Pedersen C, Skinhoj P, Pedersen B K. Clinical progression of HIV infection: role of NK cells. Scandinavian Journal of Immunology. 46:1997;91-95.
48. Ullum H, Cozzi-Lepri A, Aladdin H. Natural immunity and HIV disease progression. AIDS. 13:1999;557-563.
49. Ironson G, Balbin E, Fletcher M A. Relative preservation of natural killer cell cytotoxicity in healthy AIDS patients with low CD4 counts. Neuroimmunomodulation. 6:1999;226.
50. Shi M, Taylor J M, Fahey J L. Early levels of CD4 neopterin, and beta 2-microglobulin indicate future disease progression. Journal of Clinical Immunology. 17:1997;43-52.
51. Klein S A, Dobmeyer J M, Dobmeyer T S. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 11:1997;1111-1118.
52. Salvaggio A, Balotta C, Galli M, Clerici M. CD4 count in HIV infection is positively correlated to interferon-gamma and negatively correlated to interleukin-10 in-vitro production. AIDS. 10:1995;449-451.
53. Amiel C, Darcissac E, Truong M J. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. Journal of Infectious Diseases. 179:1999;83-91.
54. Fauci A S. Host factors and the pathogenesis of HIV-induced disease. Nature. 384:1996;529-534.
55. Naora H, Gougeon M L. Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15. Immunology Letters. 68:1999;359-367.
56. Rubartelli A, Poggi A, Sitia R, Zocchi M A. HIV-1 Tat: a polypeptide for all seasons. Immunology Today. 19:1998;543-545.
57. Prins M, Veugelers P J. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS. 11:1997;621-631.
58. Evans D L, Leserman J, Perkins D O. Severe life stress as a predictor of early disease progression in HIV infection. American Journal of Psychiatry. 154:1997;630-634.
59. Cole, S, W, Kemeny, M, E, Psychosocial influences in the progression of HIV infection, Ader, R, AFelten, D, LCohen, N, Psychoneuroimmunology, San Diego, Academic Press.
60. Kemeny M E, Dean L. Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDS Education Prevention. 7:1995;36-47.
61. Leserman J, Petitto J M, Perkins D O. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. Archives of General Psychiatry. 54:1997;279-285.
62. Goodkin K, Feaster D J, Tuttle R. Bereavement is associated with time-dependent decrements in cellular immune function in asymptomatic human immunodeficiency virus type 1-seropositive homosexual men. Clinical and Diagnostic Laboratory Immunology. 3:1996;109-118.
63. Kessler R C, Foster C, Joseph J. Stressful life events and symptom onset in HIV infection. American Journal of Psychiatry. 148:1991;733-738.
64. Rabkin J G, Williams J BW, Remien R H. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIV-positive homosexual men. Archives of General Psychiatry. 48:1991;111-119.
65. Kemeny M E, Weiner H, Taylor S E. Repeated bereavement, depressed mood, and immune parameters in HIV seropositive and seronegative gay men. Health Psychology. 13:1994;14-24.
66. Burack J H, Barrett D C, Stall R D. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. Journal of the American Medical Association. 270:1993;2568-2573.
67. Lyketsos C G, Hoover D R, Guccione M. Depressive symptoms as predictors of medical outcomes in HIV infection. Journal of the American Medical Association. 270:1993;2563-2567.
68. Mayne T J, Vittinghoff E, Chesney M A. Depressive affect and survival among gay and bisexual men infected with HIV. Archives of Internal Medicine. 156:1996;2233-2238.
69. Patterson T L, Shaw W S, Semple S J. Relationship of psychosocial factors to HIV disease progression. Annals of Behavioral Medicine. 18:1996;30-39.
70. Vassend O, Eskild A, Halvorsen R. Negative affectivity, coping, immune status, and disease progression in HIV infected individuals. Psychology and Health. 12:1997;375-388.
71. +cell decline in HIV infection. Journal of Psychosomatic Research. 42:1997;379-390.
72. Solano L, Costa M, Salvati S. Psychosocial factors and clinical evolution in HIV-1 infection: a longitudinal study. Journal of Psychosomatic Research. 37:1993;39-51.
73. Kemeny, M, Duran, R, Taylor, S, Chronic depression predicts CD4 decline over a five year period in HIV seropositive men, 1990.
74. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Archives of General Psychiatry. 49:1992;396-401.
75. Ironson G, Friedman A, Klimas N. Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus. International Journal of Behavioral Medicine. 1:1994;90-105.
76. Blomkvist V, Theorell T, Jonsson H. Psychosocial self-prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection. Psychotherapy and Psychosomatics. 62:1994;185-192.
77. Mulder C L, Antoni M H, Dulvenvoorden H J. Active confrontational coping predicts decreased clinical progression over a one-year period in HIV-infected homosexual men. Journal of Psychosomatic Research. 39:1995;957-965.
78. Reed G M, Kemeny M E, Taylor S E. Realistic acceptance as a predictor of decreased survival time in gay men with AIDS. Health Psychology. 13:1994;299-307.
79. Mulder C L, de Vroome E MM, van Griensven G JP. Avoidance as a predictor of the biological course of HIV infection over a 7-year period in gay men. Health Psychology. 18:1999;107-113.
80. Mulder C L, de Vroome E M, van Griensen G, Antoni M. Distraction as a predictor of the biological course of HIV-1 infection over a 7 year period in gay men. Psychosomatic Medicine. 57:1995;67.
81. Reed G M, Kemeny M E, Taylor S E, Visscher B R. Negative HIV-specific expectancies and AIDS-related bereavement as predictors of symptom onset in asymptomatic HIV-positive gay men. Health Psychology. 18:1999;354-363.
82. Segerstrom S C, Taylor S E, Kemeny M E. Casual attributions predict rate of immune decline in HIV-seropositive gay men. Health Psychology. 15:1996;485-493.
83. Bower J E, Kemeny M E, Taylor S E, Fahey J L. Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. Journal of Consulting and Clinical Psychology. 66:1998;979-986.
84. Theorell T, Blomkvist V, Jonsson H. Social support and the development of immune function in human immunodeficiency virus infection. Psychosomatic Medicine. 57:1995;32-36.
85. Eich-Höchli D, Niklowitz M W, Lüthy R, Opravil M. Are immunological markers, social and personal resources, or a complaint-free state predictors of progression among HIV-infected patients? Acta Psychiatrica Scandinavica. 95:1997;476-484.
86. Miller G E, Kemeny M E, Taylor S E. Social relationships and immune processes in HIV seropositive gay and bisexual men. Annals of Behavioral Medicine. 19:1997;139-151.
87. Miller G E, Cole S W. Social relationships and the progression of human immunodeficiency virus infection: A review of the evidence and possible underlying mechanisms. Annals of Behavioral Medicine. 20:1998;181-189.
88. Leserman J, Jackson E D, Petitto J M. Progression to AIDS: The effects of stress, depressive symptoms, and social support. Psychosomatic Medicine. 61:1999;397-406.
89. Capitano J P, Lerche N W. Social separation, housing relocation, and survival in simian AIDS: A retrospective analysis. Psychosomatic Medicine. 60:1998;235-244.
90. Cole S W, Kemeny M E, Taylor S E, Visscher B R. Elevated physical health risk among gay men who conceal their homosexual identity. Health Psychology. 15:1996;243-251.
91. Cole S W, Kemeny M E, Taylor S E. Social identify and physical health: Accelerated HIV progression in rejection-sensitive gay men. Journal of Personality and Social Psychology. 72:1997;320-335.
92. Solomon G, Temoshok L, O'Leary A, Zich J. An intensive psychoimmunologic study of long-surviving persons with AIDS. Pilot work, background studies, hypotheses, and methods. Annals of the New York Academy of Sciences. 496:1987;647-655.
93. Moss A O, Bacchetti P, Osmond D. Seropositivity for HIV and development of AIDS or AIDS-related condition: Three year follow-up of the San Francisco General Hospital cohort. British Medical Journal. 296:1988;745-752.
94. Ironson G, Solomon G, Cruess D. Psychosocial factors related to long-term survival with HIV/AIDS. Clinical Psychology and Psychotherapy. 2:1995;249-266.
95. Herbert T B, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosomatic Medicine. 55:1993;364-379.
96. +people with CD4 counts under 50. Neuroimmunomodulation. 6:1999;204.
97. Rabin B S. Stress immune function and health. The Connection. 1999;Wiley-Liss, Pittsburg.
98. Ironson G, Antoni M, Lutgendorf S. Can psychological interventions affect immunity and survival? Present findings and suggested targets with a focus on cancer and human immunodeficiency virus. Mind/Body Medicine. 1:1995;2.
99. Bartrop R, Lazarus L, Luckhurst E. Depressed lymphocyte function after bereavement. Lancet. i:1977;834-836.
100. Kiecolt-Glaser J K, Fisher L, Ogrocki P. Marital quality, marital disruption, and immune function. Psychosomatic Medicine. 49:1987;13-34.
101. Linn B S, Linn M W, Jensen J. Anxiety and immune responsiveness. Psychological Reports. 49:1981;969-970.
102. Schleifer S J, Keller S E, Ronald B N. Major depressive disorder and immunity. Archives of General Psychiatry. 48:1989;81-87.
103. Maes M, Stevens W J, Declerck L S. Significantly increased expression of T-cell activation markers (Interleukin-2 and HLA-DR) in depression: Further evidence for an inflammatory process during that illness. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 17:1993;241-255.
104. Irwin M, Daniels M, Smith T L. Impaired natural killer cell activity during bereavement. Brain, Behavior and Immunity. 1:1987;98-104.
105. Glaser R, Rice J, Speicher C E. Stress depresses interferon production concomitant with a decrease in natural killer cell activity. Behavioral Neurosciences. 100:1986;675-678.
106. Kiecolt-Glaser J K, Garner W, Speicher C E. Psychosocial modifiers of immunocompetence in medical students. Psychosomatic Medicine. 46:1984;7-14.
107. Irwin M, Caldwell C, Smith T. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Archives of General Psychiatry. 47:1990;713-719.
108. Evans D L, Folds J D, Petitto J M. Circulating natural killer cell phenotypes in men and women with major depression. Archives of General Psychiatry. 49:1992;399-395.
109. Ironson G H, Wynings C, Schneiderman N. Posttraumatic stress symptoms, intrusive thoughts, loss, and immune function after hurricane Andrew. Psychosomatic Medicine. 59:1997;128-141.
110. Glaser R, Pearson G R, Jones F J. Stress-related activation of Epstein-Barr Virus. Brain, Behavior, and Immunity. 5:1991;219-232.
111. Kasl S V, Evans A S, Niederman J G. Psychosocial risk factors in the development of infectious mononucleosis. Psychosomatic Medicine. 41:1979;445-466.
112. Esterling B A, Antoni M H, Kumar M, Schneiderman N. Emotional repression, stress disclosure responses, and Epstein-Barr capsid antigen titers. Psychosomatic Medicine. 52:1990;397-410.
113. Kemeny M E, Cohen F, Zegans L S, Conant M A. Psychological and immunological predictors of genital herpes recurrence. Psychosomatic Medicine. 51:1989;195-208.
114. Goldmeier D, Johnston A. Does psychiatric illness affect the recurrence rate of genital herpes? British Journal of Venereal Diseases. 54:1982;40-43.
115. Bonneau R H, Sheridan J F, Feng N, Glaser R. Stress-induced suppression of herpes simplex virus (HSV)-specific cytotoxic T lymphocyte and natural killer cell activity and enhancement of acute pathogenesis following local HSV infection. Brain, Behavior, and Immunity. 5:1991;170-192.
116. Sonnenfeld G, Cunnick J E, Armfield A V. Stress-induced alterations in interferon production and class II histocompatibility antigen expression. Brain, Behavior, and Immunity. 6:1992;170-178.
117. Glaser R, Kennedy S, Lafuse W P. Psychological stress-induced modulation of IL-2 receptor gene expression and IL-2 production in peripheral blood leukocytes. Archives of General Psychiatry. 47:1990;707-712.
118. Kiecolt-Glaser J K, Glaser R, Gravenstein S. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proceedings of the National Academy of Sciences of the USA. 93:1996;3043-3047.
119. Glaser R, Kiecolt-Glaser J K, Bonneau R. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosomatic Medicine. 54:1992;22-29.
120. Goodkin K, Feaster D J, Asthana D. A bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visits. Clinical and Diagnostic Laboratory Immunology. 5:1998;382-391.
121. Ironson G, LaPerriere A, Antoni M. Changes in immune and psychological measures as a function of anticipation and reaction to news of HIV-1 antibody status. Psychosomatic Medicine. 52:1990;247-270.
122. Ironson G, Field T, Scafidi F. Massage therapy is associated with enhancement of the immune system's cytotoxic capacity. International Journal of Neuroscience. 84:1996;205-217.
123. Robertson K R, Wilkins J W, Handy J. Psychoimmunology and AIDS: Psychological distress and herpes simplex virus in human immunodeficiency virus infected individuals. Psychology and Health. 8:1993;317-327.
124. Esterling B A, Antoni M H, Schneiderman N. Psychosocial modulation of antibody to Epstein-Barr viral capsid antigen and human herpes virus type-6 in HIV-1-infected and at-risk gay men. Psychosomatic Medicine. 54:1992;354-371.
125. Lutgendorf S K, Antoni M H, Ironson G. Cognitive-behavioral stress management decreases dysphoric mood and herpes simplex virus-type 2 antibody titers in symptomatic HIV-seropositive gay men. Journal of Consulting and Clinical Psychology. 35:1997;31-43.
126. Watkins L R, Maier S F, Goehler L E. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness response, and pathological pain states. Pain. 63:1996;284-302.
127. Nair M PN, Schwartz S A. Synergistic effect of cortisol and HIV-1 envelope peptide on the NK activity of normal lymphocytes. Brain, Behavior, and Immunity. 9:1995;20-30.
128. Cupps T, Fauci A. Corticosteroid-mediated immunoregulation in man. Immunology Reviews. 65:1982;133-155.
129. Cole S W, Korin Y D, Fahey J L, Zack J A. Norepinephrine accelerated HIV replication via protein kinase A-dependent effects on cytokine production. Journal of Immunology. 161:1998;610-616.
130. Rabkin J G, Ferrando S J. DHEA and HIV illness. The Aids Reader. 7:1997;28-36.
131. Cruess D G, Antoni M H, Kumar M. Cognitive-behavioral stress management buffers decreases in dehdroepiandrosterone sulfate (DHEA-S) and increases in the cortisol/DHEA-S ration and reduces mood disturbance and perceived stress among HIV-seropositive men. Psychoneuroendocrinology. 24:1999;537-549.
132. Villee C A, Solomon E P, Martin C E. Biology. 1989;Saunders College Publishing, Fort Worth. p. 508.
133. Ironson, G, Solomon, G, Balbin, Characteristics of long-term survivors of AIDS, 1998.